Mcp Sf Ratiopharm (Metoclopramide Hydrochloride)

Metoclopramide hydrochloride works by competitively blocking dopamine D2 receptors in the chemoreceptor trigger zone of the brain, which reduces the vomiting reflex. It also enhances acetylcholine release in the gastrointestinal tract, promoting smooth‑muscle contraction and accelerating gastric emptying.

The dosage of Mcp Sf Ratiopharm is determined by the prescribing clinician based on the patient’s specific condition, severity of symptoms, age, renal and hepatic function, and other individual factors. The prescriber will set the appropriate dose and administration schedule.

Metoclopramide hydrochloride is classified as Pregnancy Category B, indicating that animal studies have not shown risk to the fetus and there are no adequate human studies. It may be used during pregnancy only if clearly needed. While it is excreted in breast milk, the decision to breastfeed should consider the potential benefits and risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if required) and assist with any necessary import documentation.

Mcp Sf Ratiopharm belongs to the dopamine antagonist class, offering both antiemetic and gastro‑prokinetic effects. Compared with serotonin‑type 5‑HT3 antagonists, it provides additional benefit of enhancing gastric motility, which can be advantageous in gastroparesis. However, dopamine antagonists may carry a higher risk of extrapyramidal side effects, so the choice depends on the clinical scenario and patient tolerance.

Mcp Sf Ratiopharm should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain its stability and potency.

The product is supplied as a sterile injectable solution for subcutaneous administration. Healthcare professionals inject the prescribed dose subcutaneously, typically in the abdomen, thigh, or upper arm, following aseptic technique and according to the prescriber’s instructions.

Serious risks include extrapyramidal reactions such as dystonia or akathisia, tardive dyskinesia with long‑term use, neuroleptic malignant syndrome, severe depression or suicidal thoughts, seizures, and hyperprolactinemia. Patients should be monitored closely for any of these events, and therapy should be discontinued if they occur.

Mcp Sf Ratiopharm is contraindicated in patients with known hypersensitivity to metoclopramide or other dopamine antagonists, in individuals with pheochromocytoma, and in those with a history of severe extrapyramidal disorders. Caution is also advised for patients with gastrointestinal obstruction, perforation, or hemorrhage.